Getting The Mouse Out Of The Medicine

Since the successful launch of Genentech Inc.'s Herceptin treatment for breast cancer last year, antibodies have become one of the hottest arenas of drug development. They now account for over 25% of the pharmaceutical products in development, according to a recent survey by the Pharmaceutical Research and Manufacturers of America. The problem is potent antibodies are notoriously difficult to manufacture.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.